Surgical Oncology · 2022 · 10 citations · 22 references
MedicineOncologyPerioperative MedicineBreast OncologyMolecular DiagnosticsMolecular OncologyBreast Cancer RecurrenceBreast Cancer Risk AssessmentCancer BiomarkersCancer Molecular DiagnosticsCirculating Tumor Dna AnalysisRecurrence MonitoringCancer Recurrence MonitoringCirculating Cell-free Dna AnalysisCirculating Tumor Dna DetectionCirculating Tumor Dna TestingCirculating Tumor MarkersClinical Utility AssessmentPredictors Of Disease RecurrencePrognostic Variables
BACKGROUND: Circulating cell-free DNA (cfDNA) is a potential non-invasive biomarker of disease status in patients with cancer, and provides important diagnostic and prognostic information in breast cancer. The goal of this study was to quantify cfDNA concentrations during the perioperative period and investigate its potential utility to detect recurrence outcomes in patients with breast cancer. METHODS: Sixty-two (n = 62) patients with non-metastatic breast cancer, undergoing curative-intent surgery were screened for inclusion. Blood samples were collected from these patients: pre-operatively (Preop) and post-operatively (PO) at either of the following PO time points; PO week 1-2, PO week 3-4 and PO weeks 5-12 following surgery. cfDNA was extracted and quantified using nanodrop spectrophotometer. RESULTS: In a cohort of 62 patients (age, median (IQR), 51.5(45.0-65.0) years), with a median follow-up of 90 months (interquartile range (IQR),60-120 months), significant association was observed between cfDNA concentrations and risk of recurrence in patients with breast cancer. The group of patients who had disease recurrence during follow-up had significantly higher cfDNA concentrations (cutoff:400 ng/ml) compared to the group of patients who remain disease-free (Preop and PO period: p < 0.0001). The median Recurrence Free Survival (RFS) between the Disease Recurrence (DR) and the Disease Free (DF) groups of patients with breast cancer were 12(20-28.5) months and 72.00 (96-120) months; p < 0.0001). Univariate and multivariate cox regression analysis indicated that postoperative cfDNA concentration (Hazard ratio:5.0, 95% Confidence Interval:1.19-21.28, p = 0.028) was an independent negative prognostic factor for RFS in patients with non-metastatic breast cancer. CONCLUSION: Our study demonstrated that high postoperative cfDNA is associated with increased risk of future recurrence in patients with non-metastatic breast cancer. Further, prospective studies are warranted to validate its clinical utility in breast cancer.
22
Rebecca L. Siegel, Jiemin Ma, Zhaohui Zou et al. · CA A Cancer Journal for Clinicians · 2014 · 11.6K citations · Full text
Detection and localization of surgically resectable cancers with a multi-analyte blood test
Joshua D. Cohen, Lu Li, Yuxuan Wang et al. · Science · 2018 · 2.8K citations
Medicine, Oncology, Cancer Screening +16
Free DNA in the serum of cancer patients and the effect of therapy.
Shalom A. Leon, B Shapiro, D.M. Sklaroff et al. · PubMed · 1977 · 1.8K citations
Medicine, Immunology, Oncology +13